Human telomerase reverse transcriptase (TERT) has been considered a potential tumor-associated antigen for active-specific immunotherapy. However, effective specific tumor antigen-specific immunity has been difficult to induce consistently by various TERT vaccine formulations. New adjuvant strategies have been employed, such as utilizing chemokines to attract T cells and antigen-presenting cells. Chemokine adjuvant strategies may enhance tumor antigen-specific immunity induced by vaccines. Therefore, we utilized chemokine ligand 21 (CCL21) as an adjuvant with a xenogeneic TERT DNA vaccine to induce tumor antigenspecific immunity against TERT-expressing breast cancer. The TERT DNA vaccine consisted of a plasmid containing the COOH terminal end of the TERT (cTERT) gene, encapsulated in multilayered liposomes with hemagglutinating virus of Japan coating. We demonstrated that CCL21 treatment before cTERT DNA vaccine, given intramuscularly, induced significantly higher anti-TERT specific cell-mediated immunity compared to cTERT DNA vaccine alone. Effective tumor antigen-specific immunity was shown both in prophylactic and therapeutic regimens against TS/A murine breast cancer. The study demonstrated that CCL21 administration before cTERT DNA vaccination significantly augmented tumor antigen-specific immunity against breast cancer.
Introduction
Vaccines using different formulations of tumor-associated antigens (TAAs) have been shown to elicit effective immune responses to cancer cells. 1 Telomerase reverse transcriptase (TERT) is the catalytic unit of telomerase, which regulates cell proliferation and immortality. 2 We chose to use human TERT (hTERT) because it is highly expressed in various malignancies, but not in most normal tissues. 3, 4 TERT expression has been related to tumor progression and survival in these malignancies. [5] [6] [7] TERT has been recognized as a potential TAA for cancerspecific immunotherapy. 8, 9 TERT-specific CD4 þ or CD8 þ T cells have been induced in vitro from healthy donors or cancer patients. [10] [11] [12] [13] [14] [15] [16] [17] [18] However, effective anti-TERT-specific tumor immunity is difficult to induce in vivo consistently. 11, 17 It is thought that the low immunopotency of various vaccine formulas is due, in part, to poor antigen presentation by antigen-presenting cells (APCs) and/or tumor cells, weak TAA immunogenicity, limited activation of effector cells by APCs and/or immune tolerance to TAAs. All of these parameters have been shown to impair effective anti-tumor immunity. 19 We have shown that xenogeneic melanoma-associated antigen DNA vaccines can generate effective tumor antigen-specific immunity against murine melanoma by inducing antigen-specific humoral and cell-mediated immune responses. [20] [21] [22] The homology between the human COOH-terminal end of TERT (cTERT) and murine cTERT is 68%. Immunization with xenogeneic TAAs has been shown to break immune tolerance in the host and activate immunity to syngeneic antigen. 23 Therefore, we expected that human cTERT would be a potential immunogen to activate immunity to murine TERT.
In the induction of effective immune responses, the chemokines play the important roles in recruiting APCs and T cells to specific sites. Specific chemokines orchestrating immune responses in both lymphoid and nonlymphoid sites have been identified. 24 chemokine ligand 21 (CCL21), in combination with xenogeneic tyrosinaserelated protein 2 (TRP2) DNA vaccine, was shown to upregulate immune responses to TRP2.
22 CCL21 (also known as secondary lymphoid tissue chemokine, TCA4, 6-Ckine, Exodus 2) is a C-C chemokine that is a ligand for CCR7. Organ sites such as lymph nodes secreting CCL21 recruit naive T cells and mature dendritic cells (DC) bearing CCR7. 25 We applied CCL21 as an adjuvant for TERT DNA vaccine against a TERT-expressing mouse breast cancer cell line (TS/A). 26 A DNA vaccine vector was constructed with cTERT fused with a ubiquitin sequence and a PAN DR T-helper epitope sequence (PADRE) to enhance protein presentation and the immunogenicity of cTERT, respectively. [27] [28] [29] Tumor antigen-specific immunity induced by TERT DNA vaccine was assessed by evaluating TERT-specific immunoglobulin (Ig)G response, delayed-type hypersensitivity (DTH), cytokine production and growth inhibition of the autologous TS/A breast tumor in Balb/c mice. Combination of CCL21 and cTERT DNA vaccine induced effective tumor antigen-specific immunity and significant growth inhibition in both prophylactic and therapeutic model of TERT-expressing breast cancer.
Materials and methods

Cell line
The murine breast cancer cell line TS/A syngeneic to Balb/c mouse was a kind gift of Dr Pier-Luigi Lollini (Bologna, Italy). 26 B16 is a murine breast cancer cell line and 4T1 is a murine melanoma cancer cell. The cells were cultured in complete medium consisting of Rosewell Park Memorial Institute (RPMI) 1640, 10% heat-inactivated fetal bovine serum, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 50 mM 2-Methoxy-1-ethanol (2-ME), 0.3% glutamine, 100 U/ml penicillin G sodium, 100 mg/ml streptomycin sulfate and 0.25 mg/ml amphotericin B (Life Technologies, Rockville, MD).
Animals
Six-week-old female Balb/c (H-2K d ) mice were purchased from Harlan (Indianapolis, IN). Animals were housed under specific pathogen-free conditions and treated according to National Institute of Health Animal Care Guidelines. The study was approved by the IACUC at Cedars Sinai Medical Center Animal Facility (Los Angeles, CA), where the experiments were performed. All animals entered into the studies were between 6 and 8 weeks old.
TERT expression vector for immunization
The hTERT (pCl-Neo-hTERT) was obtained from Dr R Weinberg (Whitehead Institute, Cambridge, MA). 30 The amino acid sequence of hTERT was analyzed for the 8-10 amino-acid peptide binding sequences for H-2K d using two computer programs, BIMAS and SYFPEITHI. 31 The COOH-terminal end of hTERT (cTERT code for amino acids 795-1132) contains peptide sequences found to have higher scores by the programs.
The cTERT gene (coding for C-terminal, was 686-1132) was isolated from pCl-Neo-hTERT and cloned into a pVax plasmid (Invitrogen, Carlsbad, CA) to produce cTERT/pVax with an ubiquitin-PADRE-cTERT fusion gene ( Figure 1a ). The sequences of the constructs were confirmed by nucleic acid sequencing.
The ubiquitin and PADRE genes were polymerase chain reaction (PCR)-amplified and cloned as an Ubiquitin-PADRE fusion gene to enhance cell-mediated immune response. [27] [28] [29] PADRE, a synthetic peptide that binds to major histocompatibility complex class II antigens promiscuously, has been shown to increase immunity in mice and in humans. 28 Ubiquitin was used to facilitate protein presentation by the cells. Ubiquinated proteins are targeted to proteosomes for degradation and subsequently presentation to CTLs. 27 Briefly, the monomer of mouse ubiquitin gene (76 amino acids) was amplified by PCR from genomic DNA isolated from mouse liver tissue using the primer set, 5 0 primer (F1): 5 0 -AGCTG GATCCGCCGCCACCATGCAGATCTTCGTGAAGA CC-3 0 and 3 0 primer(R1): 5 0 -CAGGGTCCAGGCA GCCACGAACTTGGCCATTGCACCTCTCAGGCGA AGGACC-3 0 . PADRE sequences encoding 13 amino acids AKFVAAWTLKAAA was fused to the ubiquitin gene to construct the ubiquitin-PADRE fusion gene, which was then inserted into a pVax vector (Invitrogen). The control vector consisted of pVax with the ubiquitin-PADRE fusion gene without cTERT gene.
Expression and purification of recombinant cTERT protein The cTERT gene (1104 bp, encoding C-terminal, 368 amino acids), as a SacI -SalI DNA fragment derived from pCl-Neo-hTERT plasmid, was cloned into the (Figure 1b) .
Preparation of HVJ-liposome
Hemagglutinating virus of Japan (HVJ)-anionic liposome was prepared as described previously. 22 A premix of lipids (egg yolk phosphatidyl-choline: 96 mg, diethyl-phosphatidyl-ethanolamine: 90 mg, egg yolk sphingomyelin: 87 mg, cholesterol: 177 mg) was dissolved in chloroform and divided into seven aliquots (Avanti Polar Lipids, Alabaster, AL). Phosphatidylserine (10 mg) was added to each aliquot and then each of the aliquots was divided into eight more aliquots in glass tubes. The lipids were dried to create a thin lipid film by evaporation. Three hundred microliters of balanced salt solution (BSS; 137 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6) containing plasmid DNA (300 mg) was added to the dried lipid mixture and vortexed eight times for 30 s with 30 s rest intervals. The mixture was sonicated for 5 s, vortexed for 30 s and incubated for 30 min in a 371C water bath. The liposome suspension was mixed with a ultravioletinactivated HVJ suspension of 10 000 hemagglutinating units and placed on ice for 10 min. The mixture was shaken and incubated for 1 h in a 371C water bath. HVJliposome complexes were separated from free HVJ and free liposomes by sucrose density-gradient centrifugation (62 800 g, 41C, 90 min). HVJ-liposomes were collected and the final volume was adjusted to 500 ml with BSS for vaccination.
Immunization and mouse tumor study Two hundred microliters of HVJ-liposome containing pVax with no gene insert (for the Mock vaccine) or cTERT/pVax (for cTERT vaccine) was injected into the hind thigh of individual mice three times with 1-week intervals. As an adjuvant, we administered 0.5 mg of murine CCL21 (6Ckine; R&D, Minneapolis, MN) 24 h before cTERT DNA vaccination at the same vaccine site (CCL21/cTERT vaccine), as described previously. 22 The same amount of CCL21 was also administered three times into the hind thigh of the mice without cTERT vaccine. Two days before the first vaccination, mice were challenged subcutaneously (s.c.) with 3 Â 10 4 of TS/A cells in 100 ml of phosphate-buffered saline (PBS) for the therapeutic vaccine model. Ten days after the third vaccination, mice were challenged s.c. with 3 Â 10 4 of TS/A cells in 100 ml of PBS for the prophylactic vaccine model. Tumor size was assessed every 2-3 days for at least 21 days after tumor challenge. Mice that developed tumors of X15 mm or tumor ulcers were killed immediately according to the regulations of animal subjects committee.
Antibody response to cTERT Serum samples from mice were collected 1 week after the last vaccination. Antibody responses to cTERT were evaluated by an affinity enzyme-linked immunosorbent assay (ELISA) as described previously. 22 At first, 0.2 mg/ well of cTERT recombinant protein was incubated for 2 h at room temperature (RT) in a Reacti-Bind metal chelate plate (Pierce, Rockford, IL). After blocking by Sea Block (Pierce) for 2 h at RT, diluted serum was applied to each well and incubated at RT for 2 h. Horseradish peroxidaseconjugated goat anti-mouse IgG2a (CalTag, Burlingame, CA) was then added and incubated for 1 h at RT. The plates were developed with ortho-phenylenediamine (Sigma) in sodium citrate solution, and then incubated with 6 N HCl to stop the reaction. The optical density (OD) was measured at 490 nm using a microplate ELISA reader (Molecular Devices, Sunnyvale, CA). Sera from the Mock vaccine mice were used as negative controls in each experiment. When the OD was three s.d. greater than the negative controls, the sample was considered positive. Each serum was diluted with physiological PBS. Each serum sample was titrated until it was considered negative. The antibody titer of each sample represented the maximum dilution factor with a positive result. The Mann-Whitney's U-test was used for statistical analysis of specific immunity protocols and antibody titers generated.
Cytokine assays
Interferon-gamma (IFN-g), interleukin-4 (IL-4), granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-a) production were evaluated as previously described. 22 We used cTERT protein for 48 h in vitro stimulation of splenocytes. Spleens were harvested 1 week after the last vaccination in both the prophylactic and therapeutic vaccine models. Spleens were mechanically disrupted and treated with red blood cell lysis buffer (Gentra systems, Minneapolis, MN) and the cells were counted and suspended in culture medium. Spleen cells were then plated in 24-well plates (4-5 Â 10 6 cells/well) complete medium consisting of RPMI 1640, 10% heat-inactivated fetal bovine serum, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 50 mM 2-ME, 0.3% glutamine, 100 U/ml penicillin G sodium, 100 mg/ml streptomycin sulfate and 0.25 mg/ml amphotericin B (Life Technologies) with or without 1 mg/ ml of recombinant cTERT protein and cultured. On the second day, the supernatant was harvested for the cytokine assay. The level of cytokines in the supernatant was evaluated using ELISA according to the manufacturer's instructions (BD Pharmingen, San Diego, CA). The Mann-Whitney's U-test was used for statistical analysis of specific immunization protocols and cytokine production.
DTH DTH was performed as described previously. 21, 22 One week after the last vaccination in prophylactic model, 10 mg of recombinant cTERT protein was injected into the hind leg footpad. The thickness of footpad was measured before and 24/48 h after injection by an One-Degree Imager meter (Dyer Company, Lancaster, PA). DTH was evaluated by the increase of footpad thickness after injection. Results were shown in units: one unit ¼ 10 À2 mm. The results were pooled for each vaccine protocol and analyzed by the Student's t-test.
Flow cytometry
Antibodies for flow cytometry were purchased from Pharmingen: fluorescein isothiocyanate (FITC) anti-
2), PE-anti CD8a, PE-isotype control (rat IgG1, rat IgG2a). Spleen cells and inguinal lymph node cells were harvested from mice in the prophylactic treatment group 1 week after the last vaccination and were cultured for 48 h in complete medium with recombinant cTERT protein, as described previously. 22 A single-cell suspension was prepared in staining buffer (The BD Biosciences, San Jose, CA). Cells were incubated with anti-FcgR2/3 (2.4G2) for 10 min at 41C to reduce nonspecific staining. Cells were stained for cell-surface antigens (30 min, 41C). Intracellular staining for IFN-g was performed after CD4 þ or CD8 þ staining according to the manufacturer's instructions (The BD Biosciences). The Mock and CCL21 alone groups were considered to be the control groups and all fluorescence-activated cell sorter (FACS) analysis used the appropriate isotype antibody controls. Flow cytometric analysis was performed on a FACScan flow cytometry (The BD Biosciences). Ten thousand gated events were collected and analyzed using Cell Quest software (The BD Biosciences).
Real-time qRT-PCR
Mouse TERT gene expression in tumor cell lines and tumors was assessed by qRT as described previously. 22 Total RNA was extracted from cells and tumors using Tri-Reagent (MRC, Cincinnati, OH), and cDNA was generated from 0.5 mg of total RNA using an oligo-dT primer set and reverse transcriptase. Specific primers and a probe for the mouse TERT were designed: forward 5 0 -CTCCACCTGCCGACCTTT-3, reverse 5 0 -CACGCA GGGTCTCAATAACA-3 0 , probe 6-FAM (6-carboxyfluorescein)-CCTCTGGCCTCGTTAAGCAGCTCA-TA MRA (6-carboxy-tetramethyl-rhodamine). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNA (mRNA) was used to determine the quantity and integrity of mRNA. 22 For determining the copy number of the mRNA, plasmids containing the specific gene PCR products were constructed using the TOPO TA cloning system (Invitrogen). A standard curve using a plasmid with the specific gene was used in all assays to determine the mRNA copy number. The amount of TERT or GAPDH mRNA was analyzed by qRT using an Icycler thermal cycler detection system and software (Bio-Rad, Hercules, CA) as described previously. 22 TERT expression was represented as TERT mRNA copies divided by GAPDH mRNA copies.
Results
Induction of humoral immune response against cTERT
We assessed c-TERT specific IgG2a antibody titers against purified recombinant cTERT protein (Table 1) . IgG2a are associated with predominantly T-helper 1 (TH1) responses. 22, 31 The CCL21/cTERT vaccine induced significantly higher IgG2a (Po0.0005) titers compared to the cTERT alone vaccine both in the prophylactic and the therapeutic vaccine models (Table 1) . Both the cTERT alone vaccine and CCL21 alone failed to induce strong IgG2a responses. The CCL21/cTERT vaccine induced significantly higher IgG2a titers compared to CCL21 alone in the prophylactic model (Po0.001) and the therapeutic model (Po0.0005). These results demonstrated that CCL21 as an adjuvant could significantly boost IgG2a response induced by cTERT vaccine, suggesting a TH1 response.
Induction of DTH against cTERT
We evaluated DTH against recombinant cTERT protein to assess cell-mediated immunity in vivo (Figure 2) . Previously, we have reported the usefulness of DTH in monitoring host cell-mediated immunity after Abbreviations: Ab, antibody; cTERT, COOH terminal end of the TERT; CCL21, chemokine ligand 21; Ig, immunoglobulin. Humoral immunity against cTERT. IgG2a responses 1 week after last vaccination were assessed by ELISA using recombinant cTERT protein in both the prophylactic vaccine model (no tumor challenge) and in the therapeutic vaccine model (tumor challenge 2 days before first immunization). Mice were challenged s. vaccination. 21, 22, 32 The CCL21/cTERT vaccine induced significantly stronger DTH at both 24 and 48 h after cTERT protein injection compared to the Mock vaccine (Po0.0005), the cTERT vaccine (Po0.01) and the CCL21 vaccine alone (Po0.001), whereas the cTERT vaccine induced significantly stronger DTH compared to the Mock vaccine (Po0.01, 48 h) and the CCL21 alone (Po0.05, 48 h). These results demonstrated that DTH induced by the cTERT vaccine can be significantly activated with CCL21.
Cytokine production
We evaluated specific cytokines (IFN-g, IL-4, GM-CSF and TNF-a) after vaccination as described previously. 22 We assessed cTERT protein for in vitro stimulation of splenocytes. One week after the last vaccination the spleens were harvested immediately in the prophylactic and therapeutic vaccine models. Splenocytes were stimulated with and without recombinant cTERT protein for 48 h to assess cytokine release. The objective was to assess cytokine production related to TH1 responses (IFN-g, GM-CSF and TNF-a) and TH2 responses (IL-4).
In the prophylactic vaccine model (Figure 3a) , the CCL21/cTERT vaccine induced significantly higher levels of IFN-g (Po0.0001), IL-4 (Po0.001) and GM-CSF (Po0.001) production when compared to the other vaccines. For TNF-a production, the CCL21/cTERT vaccine induced significantly higher levels compared to the other vaccines without cTERT protein stimulation (Po0.0001), but it induced a higher level of TNF-a production only compared to the Mock vaccine with cTERT stimulation (Po0.05).
In the therapeutic vaccine model (Figure 3b) , the CCL21/cTERT vaccine induced significantly higher levels of IFN-g (Po0.0005), GM-CSF (Po0.0005) and TNF-a (Po0.01) production compared to the other vaccines. For IL-4 production, the CCL21/cTERT vaccine induced a significantly higher level only compared to the Mock vaccine (Po0.05).
In vitro sensitization with cTERT protein stimulated IFN-g and TNF-a production, but not IL-4 production, in all types of vaccines, both in the prophylactic and the therapeutic vaccine models. However, in vitro sensitization with cTERT protein did not enhance GM-CSF production in the CCL21/cTERT vaccine. In general, for both treatment regimens, CCL21/cTERT produced large amounts of specific cytokines with or without stimulation by cTERT protein compared to CCL21 or cTERT alone in vitro.
Induction of tumor antigen-specific immunity
Tumor antigen-specific immunity was assessed in both the prophylactic and the therapeutic vaccine models to determine their efficacy (Figure 4) . The CCL21/cTERT vaccine showed significant inhibition of tumor growth when compared to the other vaccines both in the prophylactic vaccine model (Figure 4a , Po0.005) and the therapeutic vaccine model (Figure 4b , Po0.05). However, the cTERT vaccine and CCL21 alone showed no significant inhibition of tumor growth compared to the Mock vaccine.
Flow cytometric analysis
Using the prophylactic treatment model, we analyzed single-cell suspensions from spleens or draining inguinal lymph nodes near the vaccine sites by flow cytometry to verify the cellular source of IFN-g production ( Table 2) . In spleens, the ratio of CD4 þ T cells or CD8 þ T cells was almost the same in all vaccines (CD4: 26.6-32.1%, CD8: 7.8-11.1%). The CCL21/cTERT vaccine produced significantly higher IFN-g both in CD4
þ T cells (9.9%) and in CD8 þ T cells (5.5%). In the other vaccines, less than 1% of CD4 þ T cells or less than 2% of CD8 þ T cells produced IFN-g.
In lymph nodes, the ratio of CD4 þ T cells varied from 50.1 to 60.4% after vaccination. The ratio of CD8 þ T cells in lymph nodes varied from 13.3 to 21.3% in vaccinetreated mice. Few or none of the CD4 þ T cells produced IFN-g in all the vaccines. The ratio of CD8 þ T cells producing IFN-g varied from 1.4 to 2.5% in vaccinetreated mice. In lymph nodes, there was no significant difference in IFN-g-producing cells between the vaccines.
TERT expression in tumors
We assessed mouse TERT gene expression in tumors and tumor cell lines by quantitative PCR (qRT-PCR). TERT expression represents mean TERT mRNA copies/10 6 GAPDH mRNA copies. The results confirmed TERT gene expression in TS/A cells (11 000 mRNA copies), which is the same as the mouse breast cancer cell line 4T1 (11 000 copies, positive control) and significantly more than the mouse melanoma cell line B16 (1100 copies). There was no significant difference in tumor TERT expression between mice treated with the Mock vaccine (7694 mRNA copies), the cTERT vaccine (5722 mRNA copies) and the CCL21/cTERT vaccine (6988 mRNA murine breast cancer expressing TERT both in prophylactic and therapeutic vaccine model when combined with CCL21 as an adjuvant. When compared to TERT vaccine or CCL21 vaccine, the CCL21/cTERT vaccine demonstrated elevated IgG2a response, DTH response and cytokine production. Thus, the effective tumor antigenspecific immunity by the CCL21/cTERT vaccine depended on augmented humoral and cell-mediated immune responses. CCL21/cTERT enhanced cytokine productions. As adjuvants, IFN-g and GM-CSF have been shown to enhance tumor antigen-specific effects. 26, 33 Enhanced production of IFN-g, GM-CSF and TNF-a are involved in tumor antigen-specific immunity. Prolonged and enhanced secretion of IFN-g by CD4 þ T cells may contribute to maintenance of an effective TERT-specific immune response and break immune tolerance. The enhancement of IL-4 and GM-CSF may contribute to maturation of DCs in spleens.
Different from DTH response, cytokine production except for TNF-a was not strongly stimulated with cTERT protein. Previously, we have shown that recombinant TRP2 protein in vitro stimulation strongly stimulated IFN-g production. 22 This may be because cTERT protein is not an efficient stimulus for in vitro cytokine production. For the in vivo DTH response, the cTERT protein should be effectively processed for antigen presentation. Determining the peptides responsible for anti-TERT immunity may be more efficient for stimulating specific cytokine production in vitro.
Elevated anti-cTERT IgG2a response was induced only by CCL21/cTERT vaccine and this anti-cTERT IgG2a response was definitely specific for cTERT. The T-cell responses in vitro. However, many of these TERT vaccine protocols failed to induce consistent effective tumor antigen-specific immunity in vivo. Vaccination using DC transfected with TERT RNA 11 or the heteroclitic peptide of hTERT 18 has shown induction of some level of tumor antigen-specific immunity against hTERT in transgenic mice expressing specific human leukocyte antigen. TERTspecific CD8 þ T cells induced by peptide stimulation have failed to recognize TERT-expressing tumor cells owing to inefficient antigen stimulation. 12 These reports suggest that TERT-specific immune response can be activated in vitro and in vivo. However, TERT-specific immune responses against tumor cells in vivo are inefficient, likely due to host immune tolerance to TERT protein.
Xenogeneic proteins are, in general, more immunogenic than syngeneic proteins and can provide robust crossstimulation. 23 Xenogeneic cTERT may contain several heteroclitic peptides and can be utilized as a polyvalent vaccine, rather than a single-peptide vaccine. We expected xenogeneic cTERT vaccine induced effective tumor antigen-specific immunity by breaking existing host immune tolerance. [22] [23] [24] [25] [26] [27] [28] [29] 33 However, xenogeneic cTERT vaccine alone could not induce effective tumor antigenspecific immunity and CCL21 administration was indispensable for effective tumor antigen-specific immunity. Prolonged and enhanced secretion of IFN-g by CD4 þ T cells may contribute to maintenance of an effective TERT-specific immune response.
We have demonstrated that CCL21 administered at the vaccination site 24 h before vaccination, activated DC infiltrates locally. 22 A recent study has also demonstrated that the CCL21 could enhance poor immunogenicity of a DNA vaccine targeted to surviving. 34 CCL21 is a multifunctional ligand and binds to both CCR7 and CXCR3. 34 The presence of CCL21 can effectively attract antigenpresenting DC and naı¨ve T cells. Activation of DC at the vaccine site and the mechanism of antigen take-up will play a significant role in generating effective tumor immunity. 35 Activated DC infiltrates in tumors may be a good prognostic factor. However, tumor-inhibiting factors can lead to inactivation of DC, thus reducing their potential role and having a negative influence. 36 The activation at vaccination sites of DCs, such as with CCL21, is likely to be more advantageous in inducing effective immunity than direct tumor challenge with CCL21 or DC. Systemic administration or administration at distant sites to the vaccine site with CCL21 had no effect, demonstrating the significance of conditioning of the local microenvironment before vaccination.
36
CCL21/cTERT induced elevated and sustained cytokine productions without cTERT protein stimulation. However, we did not observe any adverse effect of the CCL21/cTERT vaccine. Previous reports also demonstrated no adverse effects caused by a TERT-specific immune response. 11, 17 A lower presentation of TERT-derived epitope in normal tissues is considered a possible reason for lack of adverse effects against normal cells.
In conclusion, the present study provides a novel approach of using CCL21 as an adjuvant to activate anti-TERT immunity. More importantly, we demonstrate that CCL21 is involved in regulation of anti-TERT humoral-and cell-mediated immunity upon DNA vaccination. Further studies will elucidate the mechanism of enhanced immunity by CCL21 in the DNA vaccine. It will also be interesting to investigate other chemokines alone or in combination with cytokines to develop stronger priming and boosting responses or to activate specific types of immune responses. Our studies also demonstrate that a large amount of TAA at the vaccine site is not needed to activate effective tumor antigen-specific immunity. In past DNA cancer vaccine approaches, there was often concern of sufficient in vivo gene transfection. To date, the field of adjuvants for augmenting tumor vaccines is poorly developed. Our approach of utilizing a natural phenomenon of immune cell orchestration by a chemokine at the vaccination site shows significant promise in generating immunity to enhance tumor antigen-specific immunity.
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